|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues: | |||||
| Grant revenue | |||||
| Collaboration revenue - related party | |||||
| Collaboration revenue | |||||
| Total revenues | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment of long-term asset | |||||
| Restructuring | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Other income: | |||||
| Interest income | |||||
| Other income (expense), net | |||||
| Interest expense related to the sale of future royalties | |||||
| Loss on extinguishment of liability related to the sale of future royalties | |||||
| Change in fair value of derivative liability | |||||
| Total other income, net | |||||
| Net income (loss) before income taxes | |||||
| Income tax expense | |||||
| Net income (loss) and comprehensive income (loss) | |||||
| Unrealized gain on marketable securities | |||||
| Net income (loss) per share attributable to common stockholders, basic | |||||
| Net income (loss) per share attributable to common stockholders, diluted | |||||
| Weighted average common shares outstanding, basic: | |||||
| Weighted average common shares outstanding, diluted: | |||||
Loading...